{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:54:17Z","timestamp":1760061257793,"version":"build-2065373602"},"reference-count":36,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T00:00:00Z","timestamp":1489104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Licarbazepine is the pharmacologically active metabolite of oxcarbazepine, a drug indicated for the treatment of partial seizures and bipolar disorders. Several HPLC methods have been developed thus far but there is lack of control for interferences from antipsychotic drugs. The aim of the present study was to develop a simple, low\u2010cost and reliable HPLC\u2010UV method for the determination of licarbazepine in human serum in the presence of co\u2010administered antiepileptic, antipsychotic and commonly prescribed drugs. Sample preparation consisted of a single protein precipitation step with methanol. Separation lasted ~9 min on a reversed\u2010phase C<jats:sub>18<\/jats:sub> column using a mobile phase composed of 50 m<jats:sc>m<\/jats:sc> sodium\u2010dihydrogen\u2010phosphate\u2010monohydrate\/acetonitrile (70:30, v\/v) delivered isocratically at 0.9 mL\/min and 30\u00b0C. Wavelength was 210 nm and calibration curve was linear with <jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup> 0.998 over the range 0.2\u201350.0 \u03bcg\/mL. Coefficient of variation was &lt;5.03% and bias &lt;\u22124.92%. Recovery ranged from 99.49 to 104.52% and the limit of detection was 0.0182 \u03bcg\/mL. No interferences from the matrix or from antiepileptic, antipsychotic and commonly prescribed drugs were observed. The method was applied to serum samples of patients under oxcarbazepine treatment and proved to be a useful tool for the therapeutic drug monitoring of licarbazepine during monotherapy or adjunctive treatment of seizures or affective disorders.<\/jats:p>","DOI":"10.1002\/bmc.3950","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T11:02:55Z","timestamp":1486638175000},"source":"Crossref","is-referenced-by-count":8,"title":["Development and validation of a reversed\u2010phase HPLC method for licarbazepine monitoring in serum of patients under oxcarbazepine treatment"],"prefix":"10.1002","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8647-4474","authenticated-orcid":false,"given":"Elias","family":"Begas","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology, School of Medicine University of Thessaly  Larissa Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Tsakalof","sequence":"additional","affiliation":[{"name":"Laboratory of Chemistry, School of Medicine University of Thessaly  Larissa Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthimios","family":"Dardiotis","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of Larissa, School of Medicine University of Thessaly  Larissa Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios Emmanouil","family":"Vatidis","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, School of Medicine University of Thessaly  Larissa Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Kouvaras","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, School of Medicine University of Thessaly  Larissa Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eftihia Konstadinos","family":"Asprodini","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, School of Medicine University of Thessaly  Larissa Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000155342.93489.fd"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1510"},{"key":"e_1_2_7_4_1","unstructured":"Bio\u2010Rad Laboratories(2016). Available from:http:\/\/wwwbio\u2010radcom\/en\u2010us\/product\/lyphochek\u2010therapeutic\u2010drug\u2010monitoring\u2010control\u2010tdm(accessed October 2016)."},{"key":"e_1_2_7_5_1","unstructured":"Chromsystems Instruments and Chemicals GmbH(2016). Available from:https:\/\/www.chromsystems.com\/products\/therapeutic\u2010drug\u2010monitoring\/antiepileptic\u2010drugs\u2010in\u2010serum\u2010plasma\u2010hplc\u201022000\u2010hr.html(accessed December 2016)."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.09.009"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S83989"},{"key":"e_1_2_7_8_1","unstructured":"European Medicines Agency(2011).Committee for Medicinal Products for Human Use Guideline on bioanalytical method validation."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00779.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200424040-00001"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-010-3673-0"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.11.904.34513"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.04.006"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/45.9.616"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181c324c8"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00338-5"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2008.276"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645110-00002"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.07.047"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1992.tb01773.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3061909"},{"key":"e_1_2_7_22_1","first-page":"28","article-title":"Statistics for laboratory method comparison studies","volume":"15","author":"Magari R. T.","year":"2002","journal-title":"BioPharm International"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.325"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342120-00002"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04234.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2008.05.003"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986709787909604"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.10.025"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31827c11e7"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2013.02.026"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007313323"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2007.08.001"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181678ecb"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb00378.x"},{"key":"e_1_2_7_36_1","unstructured":"US Department of Health and Human Services for Food and Drug Administration(2001).Guidance for Industry Bioanalytical Method Validation."},{"key":"e_1_2_7_37_1","first-page":"1","article-title":"Simultaneous determination of ten antiepileptic drugs in human plasma by liquid chromatography and tandem mass spectrometry with positive\/negative ion\u2010switching electrospray ionization and its application in therapeutic drug monitoring","volume":"00","author":"Yin L.","year":"2016","journal-title":"Journal of Separation Science"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.3950","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.3950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:50:56Z","timestamp":1760046656000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.3950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,10]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1002\/bmc.3950"],"URL":"https:\/\/doi.org\/10.1002\/bmc.3950","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"type":"print","value":"0269-3879"},{"type":"electronic","value":"1099-0801"}],"subject":[],"published":{"date-parts":[[2017,3,10]]},"article-number":"e3950"}}